Comments on: Dendreon Immune Booster for Prostate Cancer Helps Men Live Longer; Shares Boom

By: Alaska offers details on in-flight Wi-Fi, but pricing still up in the air | Erik Bowman

Wed, 15 Apr 2009 15:03:00 +0000

[...] and analysts that the results were "unambiguous” in terms of prolonging survival, reports [...]

By: Verizon Wireless hiring 250 « Erik Bowman’s Blog

Verizon Wireless hiring 250 « Erik Bowman’s Blog — Wed, 15 Apr 2009 12:50:50 +0000

[...] and analysts that the results were "unambiguous” in terms of prolonging survival, reports [...]

By: News, Money and Drugs for April 14, 2009 | IguanaBio - A Daily Biotech and Pharma Tabloid - Gossip, News, Research, Humor and Updates on the Latest Events in Biotech and Pharma - Unique, Insightful, Truthful, Sometimes Sneaky

Wed, 15 Apr 2009 00:38:35 +0000

[...] Provenge met its primary endpoint. See our original post and our Twitter page for the details. Xconomy and the WSJ also had good takes. Some analysts, however, are still skeptical because the full data [...]

By: The Medical Quack: Provenge – the Verdict is Near for Dendreon’s Prostate Cancer Drug

Tue, 14 Apr 2009 23:10:16 +0000

[...] http://www.xconomy.com/seattle/2009/04/14/dendreon-immune-booster-for-prostate-cancer-succeeds-helps... [...]

By: space_mase

space_mase — Tue, 14 Apr 2009 21:48:52 +0000

This looks familiar. “Dendreon didn’t provide specifics about the trial outcome in today’s release, such as the magnitude of the survival benefit, or the degree of statistical significance of the finding, which measures how confident statisticians are that the finding isn’t a fluke.”

Investors make certain to collect your earnings, don’t be a bag-holder.